XML 86 R54.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Selected quarterly financial data (unaudited) (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Selected Quarterly Financial Information [Abstract] |
Summary of Selected Quarterly Financial Data (unaudited) | Selected unaudited quarterly financial data has been recast for discontinued operations for the years 2023 and 2022 and is summarized below:
| 2023 |  | 2022
(Dollars in Millions Except Per Share Data) | First Quarter(1) | Second Quarter | Third Quarter(2) | Fourth Quarter(3) |  | First Quarter(4) | Second Quarter | Third Quarter | Fourth Quarter(5)
Segment sales to customers |  |  |  |  |  |  |  |  |
Innovative Medicine | $13,413 | 13,731 | 13,893 | 13,722 |  | 12,869 | 13,317 | 13,214 | 13,163
MedTech | 7,481 | 7,788 | 7,458 | 7,673 |  | 6,971 | 6,898 | 6,782 | 6,776
Total sales | 20,894 | 21,519 | 21,351 | 21,395 |  | 19,840 | 20,215 | 19,996 | 19,939
Gross profit | 14,207 | 15,057 | 14,745 | 14,597 |  | 13,822 | 13,893 | 13,824 | 13,855
Earnings (Loss) before provision for taxes on income | (1,287) | 6,306 | 5,217 | 4,826 |  | 5,203 | 5,144 | 5,172 | 3,840
Net earnings (loss) from continuing operations | (491) | 5,376 | 4,309 | 4,132 |  | 4,571 | 4,262 | 4,310 | 3,227
Net earnings (loss) from discontinued operations, net of tax | 423 | (232) | 21,719 | (83) |  | 578 | 552 | 148 | 293
Net earnings (loss) | (68) | 5,144 | 26,028 | 4,049 |  | 5,149 | 4,814 | 4,458 | 3,520
Basic net earnings(loss) per share: |  |  |  |  |  |  |  |  |
Basic net earnings (loss) per share from continuing operations | (0.19) | 2.07 | 1.71 | 1.71 |  | 1.74 | 1.62 | 1.64 | 1.24
Basic net earnings (loss) per share from discontinued operations | 0.16 | (0.09) | 8.61 | (0.03) |  | 0.22 | 0.21 | 0.06 | 0.11
Basic net earnings (loss) per share | (0.03) | 1.98 | 10.32 | 1.68 |  | 1.96 | 1.83 | 1.70 | 1.35
Diluted net earnings (loss) per share: |  |  |  |  |  |  |  |  |
Diluted net earnings (loss) per share from continuing operations | (0.19) | 2.05 | 1.69 | 1.70 |  | 1.71 | 1.60 | 1.62 | 1.22
Diluted net earnings (loss) per share from discontinued operations | 0.16 | (0.09) | 8.52 | (0.03) |  | 0.22 | 0.20 | 0.06 | 0.11
Diluted net earnings (loss) per share | (0.03) | 1.96 | 10.21 | 1.67 |  | 1.93 | 1.80 | 1.68 | 1.33
(1)The fiscal first quarter of 2023 includes a $6.9 billion charge related to talc matters. (2)The fiscal third quarter of 2023 includes; a non-cash gain on the exchange offer of $21.0 billion that was recorded in Net earnings from discontinued operations, net of taxes; $0.6 billion related to the unfavorable change in the fair value of the retained stake in Kenvue and $0.4 billion related to the partial impairment of Idorsia convertible debt and the change in the fair value of the Idorsia equity securities held. (3)The fourth quarter of 2023 includes favorable changes in the fair value of securities of $0.4 billion (4)In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462). (5)The fiscal fourth quarter of 2022 includes one-time COVID-19 Vaccine related exit costs of $0.8 billion.

X
- Definition Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 270 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482964/270-10-50-1 + Details
Name: | us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SelectedQuarterlyFinancialInformationAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration